This Week in Rheumatology — Jul 30, 2026

Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning targeted biological therapies in vasculitis, novel autoantibody and proteomic biomarkers in connective tissue diseases, and genetic overlap in rheumatoid arthritis. Let's dive in.

We begin with vasculitis and inflammatory myopathies. In the Annals of the Rheumatic Diseases, Schmidt and colleagues evaluated the two-year outcomes of upadacitinib continuation versus withdrawal in giant cell arteritis from the SELECT-GCA trial [1]. Among patients who achieved at least 24 weeks of sustained remission by week 52, continuing upadacitinib 15 milligrams daily compared with switching to placebo resulted in substantially fewer disease flares, dropping from roughly 60% down to just 7%, while greater than doubling the maintenance of glucocorticoid-free remission from 31% to nearly 72%, alongside a median glucocorticoid exposure of zero milligrams versus over 1,000 milligrams. Safety remained consistent with the established profile through two years [1]. Turning to autoantibody pathomechanisms, Pinal-Fernandez and colleagues utilized spatial transcriptomics and bulk RNA sequencing across 814 muscle biopsies in the same journal to demonstrate that autoantibody internalization drives tissue injury in autoimmune diseases [2]. Electroporation of purified patient immunoglobulin G into healthy primary cells successfully recapitulated disease-specific transcriptional programs, revealing distinct pathways such as type I interferon and transforming growth factor-beta signaling in anti-Mi2 dermatomyositis, and type II interferon signaling in anti-PM/Scl scleromyositis, alongside direct evidence of immunoglobulin RNA transfer from antibody-secreting cells to adjacent target cells [2]. In juvenile dermatomyositis, Codes-Méndez and colleagues publishing in Rheumatology investigated interferon-related gene expression and found that type-I interferon transcripts and CXCL10 correlated strongly with muscle and skin disease activity, while CXCL9 associated with interstitial lung disease and interleukin-18 associated with calcinosis, cutaneous ulceration, and gastrointestinal involvement, with transcript levels successfully tracking clinical response to baricitinib [6].

Next, we examine systemic sclerosis and associated pulmonary manifestations. Gerges and colleagues utilized an unbiased high-throughput plasma proteomic approach across discovery and replication cohorts in the Annals of the Rheumatic Diseases to identify novel circulating biomarkers for systemic sclerosis-related interstitial lung disease and progressive pulmonary fibrosis [3]. Out of over 1,500 quantified proteins, surfactant protein D was successfully validated as being significantly elevated in systemic sclerosis with interstitial lung disease compared to without, while matrix metalloproteinase 8 independently predicted progressive pulmonary fibrosis and improved risk stratification when added to standard clinical variables [3]. Exploring vascular phenotypes in the same condition, Parker and colleagues analyzed data from the Australian Scleroderma Cohort Study in Rheumatology, revealing that systemic sclerosis patients in the top quartile of vascular cell adhesion molecule 1 had roughly double the all-cause mortality risk, driven primarily by significantly elevated rates of pulmonary arterial hypertension, myocardial disease, and digital ulcers, independent of interstitial lung disease severity [4]. Expanding our view to overlapping syndromes, Robert and group evaluated 60 anti-Ku antibody-positive patients across French university centers in RMD Open, finding that interstitial lung disease was present in 39% of patients, predominantly as fibrotic non-specific interstitial pneumonia, and progressed in 75% of cases over a median follow-up of four years, with male sex and baseline pulmonary fibrosis independently reducing survival [7].

We shift now to systemic lupus erythematosus and rheumatoid arthritis. Piunno and colleagues investigated prolonged serologically active clinically quiescent systemic lupus erythematosus in Rheumatology, defining it as at least six months of elevated anti-double-stranded DNA antibodies or low C3 without clinical activity [5]. Over a 3.3-year mean follow-up, nearly two-thirds of these quiescent patients experienced a clinical flare, with visit-by-visit analyses confirming that higher anti-double-stranded DNA and lower C3 levels independently predicted subsequent flares [5]. In lupus nephritis, Sako and collaborative researchers examined biopsy-confirmed cases in Lupus Science and Medicine, demonstrating that elevated circulating kidney injury molecule-1 levels at the time of renal biopsy were independently associated with increased long-term risks of lupus nephritis relapse [9]. Turning to early rheumatoid arthritis, Brevet and colleagues analyzed data from the French ESPOIR cohort in Arthritis and Rheumatology, evaluating anti-carbamylated fibrinogen antibodies of immunoglobulin G and immunoglobulin A isotypes [8]. While baseline levels did not predict therapeutic response, patients in the highest quartile of anti-carbamylated fibrinogen immunoglobulin G, as well as those with detectable immunoglobulin A isotype, demonstrated a significantly increased risk of rapid radiographic and structural progression, highlighting their value for early prognostic stratification [8]. Finally, addressing comorbidity genetics, Ke and colleagues performed a genome-wide cross-trait analysis in Rheumatology leveraging large-scale European databases to explore the shared architecture between rheumatoid arthritis and ten psychiatric disorders [10]. The authors identified significant positive genetic correlations with seven psychiatric disorders, uncovering 61 pleiotropic loci and 208 pleiotropic genes involved in immune responses, alongside Mendelian randomization supporting bidirectional causality with schizophrenia and causal roles for depression, anxiety, and post-traumatic stress disorder in increasing rheumatoid arthritis risk [10].

If you only have time for one paper this week, make it the evaluation of upadacitinib continuation versus withdrawal in giant cell arteritis by Schmidt and colleagues in the Annals of the Rheumatic Diseases [1]. This trial provides definitive, two-year evidence that maintaining therapy prevents disease flares and preserves steroid-free remission in patients who have achieved initial disease control.

Here are the key takeaways from this week in Rheumatology. Continuing upadacitinib through two years in giant cell arteritis dramatically reduces disease flares and maintains glucocorticoid-free remission. Spatial transcriptomics confirms that autoantibody internalization is a direct driver of tissue injury across multiple connective tissue diseases. In systemic sclerosis, plasma surfactant protein D and matrix metalloproteinase 8 emerge as robust validated biomarkers for interstitial lung disease and progressive fibrosis. Persistent serological activity in clinically quiescent lupus warrants close monitoring, as biomarker fluctuations strongly predict future flares. And finally, genetic pleiotropy between rheumatoid arthritis and psychiatric disorders highlights shared immune-inflammatory pathways underpinning clinical comorbidity.

That's your roundup for This Week in Rheumatology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.